http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Halobacterium salinarum Strain MMD047 -A Low-salt Adapted Member of the Halobacteriaceae?
Aharon Oren,Antonio Ventosa 한국생물공학회 2009 Biotechnology and Bioprocess Engineering Vol.14 No.6
In a paper recently in Biotechnology and Bioprocess Engineering (vol. 14, pp. 67-75), Shanmughapriya and coworkers described a prokaryote (strain MMD047) isolated from a marine sponge, which they classified as a strain of Halo-bacterium salinarum. As the strain grows at low salinity only, its behavior is greatly different from that of other Halo-bacterium isolates . In spite of multiple requests, the strain has not been made available for further studies and we therefore call upon the authors of the paper to release their interesting isolate for an in-depth taxonomic characterization In a paper recently in Biotechnology and Bioprocess Engineering (vol. 14, pp. 67-75), Shanmughapriya and coworkers described a prokaryote (strain MMD047) isolated from a marine sponge, which they classified as a strain of Halo-bacterium salinarum. As the strain grows at low salinity only, its behavior is greatly different from that of other Halo-bacterium isolates . In spite of multiple requests, the strain has not been made available for further studies and we therefore call upon the authors of the paper to release their interesting isolate for an in-depth taxonomic characterization
Proposed minimal standards for the use of genome data for the taxonomy of prokaryotes
Chun, Jongsik,Oren, Aharon,Ventosa, Antonio,Christensen, Henrik,Arahal, David Ruiz,da Costa, Milton S.,Rooney, Alejandro P.,Yi, Hana,Xu, Xue-Wei,De Meyer, Sofie,Trujillo, Martha E. Microbiology Society 2018 International journal of systematic and evolutiona Vol.68 No.1
Fabio Minutoli,Davide Cardile,Riccardo Laudicella,Antonio Ventosa,Benedetta Pagano,Sergio Baldari 대한핵의학회 2021 핵의학 분자영상 Vol.55 No.1
Purpose Peptide receptor radionuclide therapy represents a therapeutic option for neuroendocrine neoplasms; to date, experiences with peptide receptor radionuclide therapy of pulmonary neuroendocrine neoplasms are still limited. We report our experience with peptide receptor radionuclide therapy of pulmonary neuroendocrine neoplasm patients. Materials and Methods Clinical records of 14 pulmonary neuroendocrine neoplasm patients (7 female and 7 male) who received at least 2 cycles of peptide receptor radionuclide therapy were retrospectively reviewed. Tumoural uptake of somatostatin analogues at pre-treatment imaging was graded as 2 to 3 in all patients. RECIST criteria were used to evaluate response. Results No treated patient had significant toxicity. Partial response was found in 3 (21.4%) patients, stable disease in 7 (50%), and progressive disease in 4 (28.6%). A statistically significant difference between disease state at enrolment and after peptide receptor radionuclide therapy was found. Conclusions Our data furtherly support peptide receptor radionuclide therapy as a safe and effective treatment of patients affected by pulmonary neuroendocrine neoplasms allowing disease control in about 71% of patients without showing significant toxicity. Other studies are needed to confirm our results.